The effect of alpha lipoic acid administration on the outcomes of assisted reproductive therapy in patients with polycystic ovarian syndrome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200905048630N4

Enrollment

Registered

2023-05-24

Start date

2023-09-23

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Poly cystic ovarian syndrome. polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: receiving oral alpha lipoic acid capsule 600 mg daily for 2 months. Intervention 2: Control group: Receiving a placebo( containing flour) daily for two months.

Eligibility

Sex/Gender

Female

Age

18 Years to 37 Years

Inclusion criteria

Inclusion criteria: Women with polycystic ovary syndrome according to the Rotterdam criteria Women of reproductive age between 18 and 37 years Candidate for in vitro fertilization No endometriosis Absence of hydrosalpinx

Exclusion criteria

Exclusion criteria: BMI=30 Secondary causes of obesity (hypothyroidism, Cushing's syndrome) High grade endometriosis III and IV Thyroid diseases Salpingitis and hydrosalpinx Congenital adrenal hyperplasia Hyperprolactinemia Ovarian secretory tumors Receipt of OCPs (steroids or other drugs that affect ovarian function, insulin sensitivity, and lipid metabolism) in the past 3 months, except for standardized PCOS treatment Lupus and autoimmune diseases Systemic diseases such as hyperlipidemia and cardiovascular metabolic syndrome Severe male factor, especially non-obstructive azoospermia (sperm count less than 5 million/ml) Receive insulin

Design outcomes

Primary

Measure	Time frame
The number of oocyte obtained. Timepoint: Two months after the start of the intervention. Method of measurement: Count the number.;The number of MII oocyte obtained. Timepoint: Two months after the start of the intervention. Method of measurement: Count the number.;Fertilization rate. Timepoint: Two months after the start of the intervention. Method of measurement: Count the number of formed zygote.	—

Measure

Time frame

The number of oocyte obtained. Timepoint: Two months after the start of the intervention. Method of measurement: Count the number.;The number of MII oocyte obtained. Timepoint: Two months after the start of the intervention. Method of measurement: Count the number.;Fertilization rate. Timepoint: Two months after the start of the intervention. Method of measurement: Count the number of formed zygote.

—

Secondary

Measure	Time frame
Biochemical pregnancy. Timepoint: 14 days after embryo transfer. Method of measurement: Measurement of beta hormone serum level.;Clinical pregnancy. Timepoint: 6 weeks after embryo transfer. Method of measurement: Sonography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Maryam Azizi Kutenaee

Bandare-abbas University of Medical Sciences

maryamazizikut86@gmail.com+98 76 3333 0755

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026